Multiple Myeloma

Multiple Myeloma

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

FDA Approves Once-Weekly Carfilzomib Combo for Relapsed or Refractory MM

The FDA has approved a combination of once-weekly carfilzomib with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (MM). This...

Medicare Part D Beneficiaries With Myeloma Receive Novel Therapies More Frequently, Have Better Survival...

People with myeloma who have prescription drug coverage under Medicare are less likely to use older cytotoxic chemotherapy and more likely to receive newly...

FDA Approves NGS-Based Test for Patients With ALL or MM

The FDA authorized the next-generation sequencing (NGS)–based ClonoSEQ assay for the measurement of minimal residual disease (MRD) in patients with acute lymphocytic leukemia (ALL)...

BCMA-Targeting CAR T-Cell Therapy Shows High Response Rate in Pretreated Myeloma

Multiple myeloma (MM) is a potential target for chimeric antigen receptor (CAR) T-cell therapies, according to final results from a first-in-human trial of B-cell...

In Myeloma, Cure or Control?

Over the past two decades, the U.S. Food and Drug Administration (FDA) has approved a number of new treatments for patients with myeloma –...

FDA Approves Triplet Regimen for Multiple Myeloma

The U.S. Food and Drug Administration approved elotuzumab in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory...
WIB_icon

MRD Negativity Measured Via Next-Generation Sequencing Predicts Long-Term Survival in Myeloma

Measuring minimal residual disease (MRD) status using next-generation sequencing (NGS) represented a prognostic biomarker for survival in patients with multiple myeloma (MM), according to...

Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma

While clinical trials of the proteasome inhibitor carfilzomib for the treatment of multiple myeloma (MM) showed varying incidence rates of cardiovascular adverse events (AEs),...

Denosumab Versus Zoledronic Acid for Reducing Time to Skeletal Events in Multiple Myeloma

Approximately 90 percent of patients diagnosed with multiple myeloma (MM) present with bone lesions and are typically treated with zoledronic acid (ZA), a potentially...

Adding Carfilzomib to Lenalidomide and Dexamethasone Extends Overall Survival in Multiple Myeloma

Compared with standard therapy of lenalidomide and dexamethasone, the addition of carfilzomib improved survival, without increasing the risk of adverse events (AEs) in patients...
Advertisement

Current Issue

December 2018, Volume 4, Issue 14

This issue features a look at the consequences of medical errors, an update on the Cancer Moonshot Initiative, a preview of 2018 ASH Annual Meeting, and more.